Research into haemophilia has resulted in important advances in both the theory and practice of human genetics. In 1935, Haldane showed that haemophilia, an X-linked recessive condition, was maintained in the population by an equilibrium between the loss of haemophilia genes, due to the reduced chance that affected males have of reproducing, and the gain of new haemophilia genes, due to mutation. This scenario results in allelic heterogeneity and explains why disease severity varies, patients are frequently sporadic, and mutations are usually different and of independent origin in every family. The small size of modern western families allows haemophilia mutations to go undetected for some generations, and artificially increases the proportion of sporadic patients. In 1952, locus heterogeneity was discovered. Thus, deficiency of coagulation factor VIII was called haemophilia A and that of factor IX named haemophilia B. This knowledge eventually led to treatments based on the administration of specific gene products missing in patients. These substances were provided by networks of haemophilia centres, and the mean life expectancy of haemophilia patients in the UK seemed to approach that of the general population. Unfortunately, however, blood-derived therapeutic agents were later shown to be the vehicle of dangerous viral infections, such as HIV-1 and hepatitis, a situation that is now compounded by concerns about transmission of prions for bovine spongiform encephalopathy. Investigators should learn from these adversities, and new therapies should be preceded and accompanied by thorough risk assessment. A proportion of patients with either haemophilia A or B become refractory to treatment because of an immune reaction against the therapeutic coagulant factor. The occurrence of this reaction, called inhibitor formation, is strongly affected by the patient’s gene defect. Thus, large gene deletions or nonsense mutations cause strong predisposition, presumably because they prevent the synthesis in the patient’s cells of any immunologically recognisable factor IX protein. Therefore, the normal gene product, absent in the patient, seems foreign to their immune system. Direct or indirect replacement therapy can result in adverse immune reactions in patients who have had no chance of developing immune tolerance to the therapeutic agent. Research is needed to learn how to prevent or overcome such reactions. The relatives of patients with haemophilia are often worried about having the disease, for although haemophilia is, by and large, manageable, treatments often cause adverse reactions. There is, therefore, demand for genetic screening, which usually involves general genetic counselling, carrier diagnosis, and, more rarely, prenatal diagnoses. Carrier tests are usually required by patients’ sisters or more distant female relatives, but in 50% of families the mother of an apparently sporadic patient will want to know if she is a carrier, and hence at high risk of having more sons with haemophilia. Concern about haemophilia depends on individual circumstances, including severity of disease in the family—some patients bleed excessively only after major trauma, whereas others bleed frequently and spontaneously. In patients with haemophilia B there is good correlation between phenotype and gene defect, so that information about the gene defect has prognostic value. So far, the phenotypic consequences of 750 different mutations have been recorded. Mutations that seriously affect the structure of factor IX result in a large reduction in the amount of circulating factor IX, whereas mutations that alter its catalytic centre or its ability to interact with factor VIII and factor X (the substrate of the complex formed by factors VIII and IX) tend to cause pronounced loss of factor IX coagulant activity. The large variety and recent origin of most haemophilia mutations complicates the genetic screening process. The best way to diagnose carriers is to test for the gene defect specific to their family. Thus, in order to provide a good screening service for those with haemophilia B, a new strategy has been introduced. This is based on the construction of a national, confidential database of gene mutations and pedigrees. The mutations are identified in one patient or carrier in every family and recorded. Thus, a family member can be screened quickly, accurately, and at a reduced cost, since only a small part of the haemophilia gene needs to be checked, dependent on which family the individual belongs to. This strategy is now in full use in the UK and in Sweden, and it represents a model for the screening of other inherited diseases characterised by a varied spectrum of genetic defects, including haemophilia A. In the UK the construction of a confidential database of haemophilia A mutations and pedigrees is well on the way. Descendants of Queen Victoria (arrow), showing inheritance of haemophilia Patients are shown as red squares, and known carriers as purple circles.
Read full abstract